Literature DB >> 18513927

Schizophrenia as a progressive brain disease.

N E M van Haren1, W Cahn, H E Hulshoff Pol, R S Kahn.   

Abstract

There is convincing evidence that schizophrenia is characterized by abnormalities in brain volume. At the Department of Psychiatry of the University Medical Centre Utrecht, Netherlands, we have been carrying out neuroimaging studies in schizophrenia since 1995. We focused our research on three main questions. First, are brain volume abnormalities static or progressive in nature? Secondly, can brain volume abnormalities in schizophrenia be explained (in part) by genetic influences? Finally, what environmental factors are associated with the brain volume abnormalities in schizophrenia? Based on our findings we suggest that schizophrenia is a progressive brain disease. We showed different age-related trajectories of brain tissue loss suggesting that brain maturation that occurs in the third and fourth decade of life is abnormal in schizophrenia. Moreover, brain volume has been shown to be a useful phenotype for studying schizophrenia. Brain volume is highly heritable and twin and family studies show that unaffected relatives show abnormalities that are similar, but usually present to a lesser extent, to those found in the patients. However, also environmental factors play a role. Medication intake is indeed a confounding factor when interpreting brain volume (change) abnormalities, while independent of antipsychotic medication intake brain volume abnormalities appear influenced by the outcome of the illness. In conclusion, schizophrenia can be considered as a progressive brain disease with brain volume abnormalities that are for a large part influenced by genetic factors. Whether the progressive volume change is also mediated by genes awaits the results of longitudinal twin analyses. One of the main challenges for the coming years, however, will be the search for gene-by-environment interactions on the progressive brain changes in schizophrenia.

Entities:  

Mesh:

Year:  2008        PMID: 18513927     DOI: 10.1016/j.eurpsy.2007.10.013

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  28 in total

1.  Premorbid multivariate markers of neurodevelopmental instability in the prediction of adult schizophrenia-spectrum disorder: a high-risk prospective investigation.

Authors:  Shana Golembo-Smith; Jason Schiffman; Emily Kline; Holger J Sørensen; Erik L Mortensen; Laura Stapleton; Kentaro Hayashi; Niels M Michelsen; Morten Ekstrøm; Sarnoff Mednick
Journal:  Schizophr Res       Date:  2012-06-02       Impact factor: 4.939

2.  The contribution of neuroimaging to understanding schizophrenia; past, present, and future.

Authors:  Iris E Sommer; René S Kahn
Journal:  Schizophr Bull       Date:  2014-10-27       Impact factor: 9.306

3.  Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study.

Authors:  Monika Vrajová; Frantisek Stastný; Jirí Horácek; Jan Lochman; Omar Serý; Sona Peková; Jan Klaschka; Cyril Höschl
Journal:  Neurochem Res       Date:  2010-03-05       Impact factor: 3.996

4.  Aging effects on regional brain structural changes in schizophrenia.

Authors:  Igor Nenadić; Heinrich Sauer; Stefan Smesny; Christian Gaser
Journal:  Schizophr Bull       Date:  2011-02-04       Impact factor: 9.306

5.  Study factors influencing ventricular enlargement in schizophrenia: a 20 year follow-up meta-analysis.

Authors:  Angelo Sayo; Robin G Jennings; John Darrell Van Horn
Journal:  Neuroimage       Date:  2011-07-20       Impact factor: 6.556

6.  Focal and global brain measurements in siblings of patients with schizophrenia.

Authors:  Heleen B M Boos; Wiepke Cahn; Neeltje E M van Haren; Eske M Derks; Rachel M Brouwer; Hugo G Schnack; Hilleke E Hulshoff Pol; René S Kahn
Journal:  Schizophr Bull       Date:  2011-01-17       Impact factor: 9.306

7.  Source-based morphometry of gray matter volume in men with first-episode schizophrenia.

Authors:  Tomás Kaspárek; Radek Marecek; Daniel Schwarz; Radovan Prikryl; Jirí Vanícek; Michal Mikl; Eva Cesková
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

8.  Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits.

Authors:  Verian Bader; Liisa Tomppo; Svenja V Trossbach; Nicholas J Bradshaw; Ingrid Prikulis; S Rutger Leliveld; Chi-Ying Lin; Koko Ishizuka; Akira Sawa; Adriana Ramos; Isaac Rosa; Ángel García; Jesús R Requena; Maria Hipolito; Narayan Rai; Evaristus Nwulia; Uwe Henning; Stefano Ferrea; Christian Luckhaus; Jesper Ekelund; Juha Veijola; Marjo-Riitta Järvelin; William Hennah; Carsten Korth
Journal:  Hum Mol Genet       Date:  2012-07-13       Impact factor: 6.150

9.  [Not Available].

Authors:  Serge A Mitelman; Emily L Canfield; Randall E Newmark; Adam M Brickman; Yuliya Torosjan; King-Wai Chu; Erin A Hazlett; M Mehmet Haznedar; Lina Shihabuddin; Monte S Buchsbaum
Journal:  Open Neuroimag J       Date:  2009-05-20

10.  Neuropathological changes in the substantia nigra in schizophrenia but not depression.

Authors:  M R Williams; K Galvin; B O'Sullivan; C D MacDonald; E W K Ching; F Turkheimer; O D Howes; R K B Pearce; S R Hirsch; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-12-29       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.